S. Punnen, M. Cooperberg, D. Amico, A. Karakiewicz, P. Moul et al., Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature, European Urology, vol.64, issue.6, pp.905-920, 2013.
DOI : 10.1016/j.eururo.2013.05.025

F. Eyben and K. Kairemo, Acquisition with 11C-choline and 18F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis, Annals of Nuclear Medicine, vol.14, issue.6, pp.385-92, 2016.
DOI : 10.1007/s12149-016-1078-7

C. Pound, A. Partin, M. Eisenberger, D. Chan, J. Pearson et al., Natural History of Progression After PSA Elevation Following Radical Prostatectomy, JAMA, vol.281, issue.17, pp.1591-1598, 1999.
DOI : 10.1001/jama.281.17.1591

D. Yates, M. Rouprêt, S. Drouin, E. Comperat, S. Ricci et al., Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy, The Prostate, vol.181, issue.3, pp.1382-1390, 2012.
DOI : 10.1002/pros.22488

C. Bluemel, M. Krebs, B. Polat, F. Linke, M. Eiber et al., 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT, Clinical Nuclear Medicine, vol.41, issue.7, pp.515-536, 2016.
DOI : 10.1097/RLU.0000000000001197

A. Afshar-oromieh, E. Avtzi, F. Giesel, T. Holland-letz, H. Linhart et al., The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.48, issue.2, pp.197-209, 2015.
DOI : 10.1007/s00259-014-2949-6

M. Eiber, T. Maurer, M. Souvatzoglou, A. Beer, A. Ruffani et al., Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy, Journal of Nuclear Medicine, vol.56, issue.5, pp.668-74, 2015.
DOI : 10.2967/jnumed.115.154153

F. Ceci, C. Uprimny, B. Nilica, L. Geraldo, D. Kendler et al., 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?, European Journal of Nuclear Medicine and Molecular Imaging, vol.3, issue.6, pp.1284-94, 2015.
DOI : 10.1007/s00259-015-3078-6

F. Verburg, D. Pfister, A. Heidenreich, A. Vogg, N. Drude et al., Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score, European Journal of Nuclear Medicine and Molecular Imaging, vol.65, issue.3, pp.397-403, 2016.
DOI : 10.1007/s00259-015-3240-1

M. Perera, N. Papa, D. Christidis, D. Wetherell, M. Hofman et al., Sensitivity, Specificity, and Predictors of Positive 68Ga?Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis, European Urology, vol.70, issue.6, pp.926-963, 2016.
DOI : 10.1016/j.eururo.2016.06.021

J. Morigi, P. Stricker, P. Leeuwen, . Van, R. Tang et al., Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy, Journal of Nuclear Medicine, vol.56, issue.8, pp.1185-90, 2015.
DOI : 10.2967/jnumed.115.160382

A. Afshar-oromieh, C. Zechmann, A. Malcher, M. Eder, M. Eisenhut et al., Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.82, issue.17, pp.11-20, 2014.
DOI : 10.1007/s00259-013-2525-5

S. Albisinni, C. Artigas, F. Aoun, I. Biaou, J. Grosman et al., Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis o, BJU International, vol.67, 2016.
DOI : 10.1111/bju.13739